… pharmaceutical support and manufacturing. Orexigen Therapeutics ( OREX ) - $231 million market cap Orexigen will release earnings May 9th amidst the ..... and Vivus ( VVUS ) earlier this year. Orexigen 's drug, Contrave, was rejected by …
… lorcaserin for obesity, in what has a become a three-way horse race with peers Vivus Inc. ( VVUS ) and Orexigen Therapeutics ( OREX ) that also have obesity drugs under late-stage development. There was no fundamental news story that can …
… Next, there is the excited speculation over progress and approval of obesity drugs from Vivus ( VVUS ), Arena ( ARNA ) and Orexigen ( OREX ) which has kept volatility flowing and given the sector more exposure. Added to that, we have the talk of unsolicited …
… optimism grows over the approval of Lorcaserin. However, this gain still pales in comparison to the rallies seen by Vivus and Orexigen ( OREX ), its peers in the obesity drug space. There is much debate on whether or not Lorcaserin will be approved, both here …
Bank of America upgrades Orexigen Therapeutics ( OREX ) to Buy with a lofty price objective of $7 as analysts with the firm identify attractive valuation and potential near-term catalysts. Shares +8.9% premarket. Post your comment!
… authorization in the EU with a new chemical entity. Orexigen Therapeutics , Inc . ( OREX ) also is in phase III with a market cap approximately ..... the chronic therapies proposed by VVUS, ARNA and OREX . In thinking about Qnexa's potential launch …
… of hopeful diet-pill makers Orexigen Therapeutics ( OREX ) and Arena Pharmaceuticals ..... the weight-loss medicine. Orexigen and Arena, neither of which ..... By the end of the session, Orexigen forfeited about a third of its …
… obesity drugs up for approval soon. Contact excitement spread to two other such pharmaceutical companies, Arena ( ARNA ) and Orexigen ( OREX ), with both companies' shares up over 15% after market. A glimmer into the future suggests the approximate $121 billion …
… lured investors with the promise of enormous returns. Everyone wants to invest in the next Amgen ( AMGN ), not the next Orexigen ( OREX ). Yet, biotech companies face unique risks that do not affect any other industry. A single drug trial can change everything …
… Smith On Stocks : Investment Opinion Orexigen ’s ( OREX ) anti-obesity drug Contrave has been ..... Contrave. In a press release yesterday, Orexigen stated that the FDA in a letter had agreed ..... which is similar to the proposal that Orexigen made to FDA that was initially rejected …